VolitionRX Limited
VNRX Healthcare Medical Devices
VolitionRX Limited’s revenue for fiscal 2025 (year ended December 2025) was $1.7 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue fell 1.97%, EPS grew 29.2%, free cash flow grew 18.6% and total debt rose 7.56%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow VNRX
VolitionRX Limited (VNRX) EV/Sales
As of 16 October 2026, VolitionRX Limited (VNRX) trades at a EV/Sales of 4.0×. Over the past ten years it has ranged from 4.0× (October 2026) to 21,629× (January 2015) — the current reading is the lowest in ten years. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 21.7× | (50.17%) |
| FY2024 | 43.6× | (42.98%) |
| FY2023 | 76.5× | (81.36%) |
| FY2022 | 410× | (75.11%) |
| FY2021 | 1,648× | (86.26%) |
| FY2020 | 11,996× | 388.34% |
| FY2019 | 2,456× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.4× | (42.08%) |
| Mar 2026 | 14.4× | (33.54%) |
| Dec 2025 | 21.7× | (61.90%) |
| Sep 2025 | 57.1× | (12.46%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation compare | −63.5× |
| CODX Co-Diagnostics, Inc. compare | −1.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| TBIO Telesis Bio Inc. compare | 0.1× |
| INBS Intelligent Bio Solutions Inc. compare | 0.2× |
| VVOS Vivos Therapeutics, Inc. compare | 0.4× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| VNRX VolitionRX Limited | 4.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)